Transcription addiction: Can we garner the Yin and Yang functions of E2F1 for cancer therapy?

Cell Death and Disease

Volumn 5, Issue 8, 2014, Pages

  Meng, P ^a   Ghosh, R ^a,b  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MICRORNA; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

CHINESE MEDICINE; DRUG RESISTANCE; HUMAN; METABOLISM; NEOPLASMS; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DRUG RESISTANCE, NEOPLASM; E2F TRANSCRIPTION FACTORS; HUMANS; MICRORNAS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; YIN-YANG;

EID: 84906885722     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.326     Document Type: Review

References (140)

1. Kovesdi I, Reichel R, Nevins JR. Identification of a cellular transcription factor involved in E1A trans-activation. Cell 1986; 45: 219-228.
2. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009; 9: 785-797.
3. Polager S, Ginsberg D. E2F - at the crossroads of life and death. Trends Cell Biol 2008; 18: 528-535.
4. Mundle SD, Saberwal G. Evolving intricacies and implications of E2F1 regulation. FASEB J 2003; 17: 569-574.
5. Bracken AP, Ciro M, Cocito A, Helin K. E2F target genes: unraveling the biology. Trends Biochem Sci 2004; 29: 409-417.
6. Yeo HC, Beh TT, Quek JJ, Koh G, Chan KK, Lee DY. Integrated transcriptome and binding sites analysis implicates E2F in the regulation of self-renewal in human pluripotent stem cells. PLoS One 2011; 6: e27231.
7. Nowak K, Kerl K, Fehr D, Kramps C, Gessner C, Killmer K et al. BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res 2006; 34: 1745-1754.
8. Polager S, Ofir M, Ginsberg D. E2F1 regulates autophagy and the transcription of autophagy genes. Oncogene 2008; 27: 4860-4864.
9. Wang B, Ling S, Lin WC. 14-3-3Tau regulates Beclin 1 and is required for autophagy. PLoS One 2010; 5: e10409.
10. Biswas AK, Johnson DG. Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage. Cancer Res 2012; 72: 13-17.
11. Garcia-Garcia A, Rodriguez-Rocha H, Tseng MT, Montes de Oca-Luna R, Zhou HS, McMasters KM et al. E2F-1 lacking the transcriptional activity domain induces autophagy. Cancer Biol Ther 2012; 13: 1091-1101.
12. Hao H, Chen C, Rao XM, Gomez-Gutierrez JG, Zhou HS, McMasters KM. E2F-1- and E2Ftr-mediated apoptosis: the role of DREAM and HRK. J Cell Mol Med 2012; 16: 605-615.
13. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996; 85: 537-548.
14. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin Jr WG, Livingston DM et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996; 85: 549-561.
15. Mans DA, Vermaat JS, Weijts BG, van Rooijen E, van Reeuwijk J, Boldt K et al. Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients. J Pathol 2013; 231: 117-129.
16. Ma X, Gao Y, Fan Y, Ni D, Zhang Y, Chen W et al. Overexpression of E2F1 promotes tumor malignancy and correlates with TNM stages in clear cell renal cell carcinoma. PLoS One 2013; 8: e73436.
17. Tian W, Cui F, Esteban MA. E2F1 in renal cancer: Mr Hyde disguised as Dr Jekyll? J Pathol 2013; 231: 143-146.
18. Rosenfeldt MT, Bell LA, Long JS, O'Prey J, Nixon C, Roberts F et al. E2F1 drives chemotherapeutic drug resistance via ABCG2. Oncogene 2013; e-pub ahead of print 25 November 2013; doi:10.1038/onc.2013.470.
19. Luo W, Huang B, Li Z, Li H, Sun L, Zhang Q et al. MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. PLoS One 2013; 8: e64759.
20. Hung JJ, Hsueh CT, Chen KH, Hsu WH, Wu YC. Clinical significance of E2F1 protein expression in non-small cell lung cancer. Exp Hematol Oncol 2012; 1: 18.
21. Carcagno AL, Ogara MF, Sonzogni SV, Marazita MC, Sirkin PF, Ceruti JM et al. E2F1 transcription is induced by genotoxic stress through ATM/ATR activation. IUBMB Life 2009; 61: 537-543.
22. Wang B, Liu K, Lin FT, Lin WC. A role for 14-3-3 tau in E2F1 stabilization and DNA damage-induced apoptosis. J Biol Chem 2004; 279: 54140-54152.
23. Stevens C, Smith L, La Thangue NB. Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 2003; 5: 401-409.
24. Berkovich E, Ginsberg D. ATM is a target for positive regulation by E2F-1. Oncogene 2003; 22: 161-167.
25. Powers JT, Hong S, Mayhew CN, Rogers PM, Knudsen ES, Johnson DG. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol Cancer Res 2004; 2: 203-214.
26. Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemela M et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov 2013; 3: 182-197.
27. Taubert S, Gorrini C, Frank SR, Parisi T, Fuchs M, Chan HM et al. E2F-dependent histone acetylation and recruitment of the Tip60 acetyltransferase complex to chromatin in late G1. Mol Cell Biol 2004; 24: 4546-4556.
28. Lang SE, McMahon SB, Cole MD, Hearing P. E2F transcriptional activation requires TRRAP and GCN5 cofactors. J Biol Chem 2001; 276: 32627-32634.
29. Galbiati L, Mendoza-Maldonado R, Gutierrez MI, Giacca M. Regulation of E2F-1 after DNA damage by p300-mediated acetylation and ubiquitination. Cell Cycle 2005; 4: 930-939.
30. Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J 2000; 19: 662-671.
31. Pediconi N, Guerrieri F, Vossio S, Bruno T, Belloni L, Schinzari V et al. hSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in response to DNA damage. Mol Cell Biol 2009; 29: 1989-1998.
32. Van Den Broeck A, Nissou D, Brambilla E, Eymin B, Gazzeri S. Activation of a Tip60/E2F1/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin. Carcinogenesis 2012; 33: 320-325.
33. Guo R, Chen J, Mitchell DL, Johnson DG. GCN5 and E2F1 stimulate nucleotide excision repair by promoting H3K9 acetylation at sites of damage. Nucleic Acids Res 2011; 39: 1390-1397.
34. Pillai S, Kovacs M, Chellappan S. Regulation of vascular endothelial growth factor receptors by Rb and E2F1: role of acetylation. Cancer Res 2010; 70: 4931-4940.
35. Kontaki H, Talianidis I. Lysine methylation regulates E2F1-induced cell death. Mol Cell 2010; 39: 152-160.
36. Cho EC, Zheng S, Munro S, Liu G, Carr SM, Moehlenbrink J et al. Arginine methylation controls growth regulation by E2F-1. EMBO J 2012; 31: 1785-1797.
37. Zheng S, Moehlenbrink J, Lu YC, Zalmas LP, Sagum CA, Carr S et al. Arginine methylation-dependent reader-writer interplay governs growth control by E2F-1. Mol Cell 2013; 52: 37-51.
38. Koon HB, Atkins MB. Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance. Expert Rev Anticancer Ther 2007; 7: 79-88.
39. Haddad MM, Xu W, Medrano EE. Aging in epidermal melanocytes: cell cycle genes and melanins. J Investig Dermatol Symp Proc 1998; 3: 36-40.
40. Haddad MM, Xu W, Schwahn DJ, Liao F, Medrano EE. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes. Exp Cell Res 1999; 253: 561-572.
41. Bandyopadhyay D, Medrano EE. Melanin accumulation accelerates melanocyte senescence by a mechanism involving p16INK4a/CDK4/pRB and E2F1. Ann N Y Acad Sci 2000; 908: 71-84.
42. Mannava S, Omilian AR, Wawrzyniak JA, Fink EE, Zhuang D, Miecznikowski JC et al. PP2A-B56alpha controls oncogene-induced senescence in normal and tumor human melanocytic cells. Oncogene 2012; 31: 1484-1492.
43. Crowe DL, Nguyen DC, Tsang KJ, Kyo S. E2F-1 represses transcription of the human telomerase reverse transcriptase gene. Nucleic Acids Res 2001; 29: 2789-2794.
44. Lacerte A, Korah J, Roy M, Yang XJ, Lemay S, Lebrun JJ. Transforming growth factorbeta inhibits telomerase through SMAD3 and E2F transcription factors. Cell Signal 2008; 20: 50-59.
45. Elliott KA, Rickords LF, Labrum JM. Transduction of E2F-1 TAT fusion proteins represses expression of hTERT in primary ductal breast carcinoma cell lines. Mol Cancer 2008; 7: 28.
46. Halaban R, Cheng E, Smicun Y, Germino J. Deregulated E2F transcriptional activity in autonomously growing melanoma cells. J Exp Med 2000; 191: 1005-1016.
47. Nelson MA, Reynolds SH, Rao UN, Goulet AC, Feng Y, Beas A et al. Increased gene copy number of the transcription factor E2F1 in malignant melanoma. Cancer Biol Ther 2006; 5: 407-412.
48. Verhaegen M, Checinska A, Riblett MB, Wang S, Soengas MS. E2F1-dependent oncogenic addiction of melanoma cells to MDM2. Oncogene 2012; 31: 828-841.
49. Nambiar S, Mirmohammadsadegh A, Hassan M, Hegemann JH, Hengge UR. Transcriptional regulation of ASK/Dbf4 in cutaneous melanoma is dependent on E2F1. Exp Dermatol 2008; 17: 986-991.
50. Alla V, Engelmann D, Niemetz A, Pahnke J, Schmidt A, Kunz M et al. E2F1 in melanoma progression and metastasis. J Natl Cancer Inst 2010; 102: 127-133.
51. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996; 271: 20608-20616.
52. von Willebrand M, Zacksenhaus E, Cheng E, Glazer P, Halaban R. The tyrphostin AG1024 accelerates the degradation of phosphorylated forms of retinoblastoma protein (pRb) and restores pRb tumor suppressive function in melanoma cells. Cancer Res 2003; 63: 1420-1429.
53. Korotayev K, Chaussepied M, Ginsberg D. ERK activation is regulated by E2F1 and is essential for E2F1-induced S phase entry. Cell Signal 2008; 20: 1221-1226.
54. Fernandez-Garcia B, Vaque JP, Herreros-Villanueva M, Marques-Garcia F, Castrillo F, Fernandez-Medarde A et al. p73 cooperates with Ras in the activation of MAP kinase signaling cascade. Cell Death Differ 2007; 14: 254-265.
55. Conde-Perez A, Larue L. PTEN and melanomagenesis. Future Oncol 2012; 8: 1109-1120.
56. Davies MA. The role of the PI3K-AKT pathway in melanoma. Cancer J 2012; 18: 142-147.
57. Madhunapantula SV, Mosca PJ, Robertson GP. The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol Ther 2011; 12: 1032-1049.
58. Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, Kulms D et al. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Investig Dermatol 2009; 129: 1500-1515.
59. Chen B, Tardell C, Higgins B, Packman K, Boylan JF, Niu H. BRAFV600E negatively regulates the AKT pathway in melanoma cell lines. PLoS One 2012; 7: e42598.
60. Chaussepied M, Ginsberg D. Transcriptional regulation of AKT activation by E2F. Mol Cell 2004; 16: 831-837.
61. Hallstrom TC, Nevins JR. Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci USA 2003; 100: 10848-10853.
62. Liu K, Graves JD, Scott JD, Li R, Lin WC. Akt switches TopBP1 function from checkpoint activation to transcriptional regulation through phosphoserine binding-mediated oligomerization. Mol Cell Biol 2013; 33: 4685-4700.
63. Liu K, Lin FT, Ruppert JM, Lin WC. Regulation of E2F1 by BRCT domain-containing protein TopBP1. Mol Cell Biol 2003; 23: 3287-3304.
64. Liu K, Paik JC, Wang B, Lin FT, Lin WC. Regulation of TopBP1 oligomerization by Akt/PKB for cell survival. EMBO J 2006; 25: 4795-4807.
65. Liu K, Luo Y, Lin FT, Lin WC. TopBP1 recruits Brg1/Brm to repress E2F1-induced apoptosis, a novel pRb-independent and E2F1-specific control for cell survival. Genes Dev 2004; 18: 673-686.
66. Dar AA, Majid S, de Semir D, Nosrati M, Bezrookove V, Kashani-Sabet M. miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem 2011; 286: 16606-16614.
67. Liu S, Tetzlaff MT, Liu A, Liegl-Atzwanger B, Guo J, Xu X. Loss of microRNA-205 expression is associated with melanoma progression. Lab Invest 2012; 92: 1084-1096.
68. Noguchi S, Mori T, Hoshino Y, Yamada N, Maruo K, Akao Y. MicroRNAs as tumour suppressors in canine and human melanoma cells and as a prognostic factor in canine melanomas. Vet Comp Oncol 2013; 11: 113-123.
69. Xu Y, Brenn T, Brown ER, Doherty V, Melton DW. Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. Br J Cancer 2012; 106: 553-561.
70. Hanna JA, Hahn L, Agarwal S, Rimm DL. In situ measurement of miR-205 in malignant melanoma tissue supports its role as a tumor suppressor microRNA. Lab Invest 2012; 92: 1390-1397.
71. Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M et al. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 2012; 11: 3067-3078.
72. Jamshidi-Parsian A, Dong Y, Zheng X, Zhou HS, Zacharias W, McMasters KM. Gene expression profiling of E2F-1-induced apoptosis. Gene 2005; 344: 67-77.
73. Dong YB, Yang HL, Elliott MJ, McMasters KM. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors. Cancer Res 2002; 62: 1776-1783.
74. Hao H, Dong YB, Bowling MT, Zhou HS, McMasters KM. Alteration of gene expression in melanoma cells following combined treatment with E2F-1 and doxorubicin. Anticancer Res 2006; 26: 1947-1956.
75. Hao H, Zhou HS, McMasters KM. Chemosensitization of tumor cells: inactivation of nuclear factor-kappa B associated with chemosensitivity in melanoma cells after combination treatment with E2F-1 and doxorubicin. Methods Mol Biol 2009; 542: 301-313.
76. Bell LA, O'Prey J, Ryan KM. DNA-binding independent cell death from a minimal proapoptotic region of E2F-1. Oncogene 2006; 25: 5656-5663.
77. Croxton R, Ma Y, Song L, Haura EB, Cress WD. Direct repression of the Mcl-1 promoter by E2F1. Oncogene 2002; 21: 1359-1369.
78. Gomez-Gutierrez JG, Garcia-Garcia A, Hao H, Rao XM, Montes de Oca-Luna R, Zhou HS et al. Adenovirus-mediated expression of truncated E2F-1 suppresses tumor growth in vitro and in vivo. Cancer 2010; 116: 4420-4432.
79. Chen KG, Valencia JC, Lai B, Zhang G, Paterson JK, Rouzaud F et al. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci USA 2006; 103: 9903-9907.
80. Saez-Ayala M, Fernandez-Perez MP, Montenegro MF, Sanchez-del-Campo L, Chazarra S, Pinero-Madrona A et al. Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res 2012; 318: 1146-1159.
81. Fernandez-Perez MP, Montenegro MF, Saez-Ayala M, Sanchez-del-Campo L, Pinero-Madrona A, Cabezas-Herrera J et al. Suppression of antifolate resistance by targeting the myosin Va trafficking pathway in melanoma. Neoplasia 2013; 15: 826-839.
82. Saez-Ayala M, Montenegro MF, Sanchez-Del-Campo L, Fernandez-Perez MP, Chazarra S, Freter R et al. Directed phenotype switching as an effective antimelanoma strategy. Cancer Cell 2013; 24: 105-119.
83. Blanchet E, Annicotte JS, Lagarrigue S, Aguilar V, Clape C, Chavey C et al. E2F transcription factor-1 regulates oxidative metabolism. Nat Cell Biol 2011; 13: 1146-1152.
84. Rabbani F, Richon VM, Orlow I, Lu ML, Drobnjak M, Dudas M et al. Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization. J Natl Cancer Inst 1999; 91: 874-881.
85. Zacharatos P, Kotsinas A, Evangelou K, Karakaidos P, Vassiliou LV, Rezaei N et al. Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human carcinomas. J Pathol 2004; 203: 744-753.
86. Zhang SY, Liu SC, Al-Saleem LF, Holloran D, Babb J, Guo X et al. E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev 2000; 9: 395-401.
87. Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD et al. E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide. Breast Cancer Res Treat 2003; 82: 11-16.
88. Hunt KK, Deng J, Liu TJ, Wilson-Heiner M, Swisher SG, Clayman G et al. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res 1997; 57: 4722-4726.
89. Narayan G, Murty VV. Integrative genomic approaches in cervical cancer: implications for molecular pathogenesis. Future Oncol 2010; 6: 1643-1652.
90. Wilting SM, de Wilde J, Meijer CJ, Berkhof J, Yi Y, van Wieringen WN et al. Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer. Genes Chromosomes Cancer 2008; 47: 890-905.
91. Wilting SM, Snijders PJ, Meijer GA, Ylstra B, van den Ijssel PR, Snijders AM et al. Increased gene copy numbers at chromosome 20q are frequent in both squamous cell carcinomas and adenocarcinomas of the cervix. J Pathol 2006; 209: 220-230.
92. Kim YT, Zhao M. Aberrant cell cycle regulation in cervical carcinoma. Yonsei Med J 2005; 46: 597-613.
93. Malinowski DP. Molecular diagnostic assays for cervical neoplasia: emerging markers for the detection of high-grade cervical disease. Biotechniques 2005; Suppl: 17-23.
94. Zheng ZM, Wang X. Regulation of cellular miRNA expression by human papillomaviruses. Biochim Biophys Acta 2011; 1809: 668-677.
95. Iwamoto M, Banerjee D, Menon LG, Jurkiewicz A, Rao PH, Kemeny NE et al. Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification. Cancer Biol Ther 2004; 3: 395-399.
96. Bramis J, Zacharatos P, Papaconstantinou I, Kotsinas A, Sigala F, Korkolis DP et al. E2F-1 transcription factor immunoexpression is inversely associated with tumor growth in colon adenocarcinomas. Anticancer Res 2004; 24: 3041-3047.
97. Elliott MJ, Dong YB, Yang H, McMasters KM. E2F-1 up-regulates c-Myc and p14(ARF) and induces apoptosis in colon cancer cells. Clinical Cancer Res 2001; 7: 3590-3597.
98. Fujita Y, Sakakura C, Shimomura K, Nakanishi M, Yasuoka R, Aragane H et al. Chromosome arm 20q gains and other genomic alterations in esophageal squamous cell carcinoma, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Hepatogastroenterology 2003; 50: 1857-1863.
99. Ebihara Y, Miyamoto M, Shichinohe T, Kawarada Y, Cho Y, Fukunaga A et al. Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression. Dis Esophagus 2004; 17: 150-154.
100. Mega S, Miyamoto M, Ebihara Y, Takahashi R, Hase R, Li L et al. Cyclin D1, E2F1 expression levels are associated with characteristics and prognosis of esophageal squamous cell carcinoma. Dis Esophagus 2005; 18: 109-113.
101. Yamazaki K, Hasegawa M, Ohoka I, Hanami K, Asoh A, Nagao T et al. Increased E2F-1 expression via tumour cell proliferation and decreased apoptosis are correlated with adverse prognosis in patients with squamous cell carcinoma of the oesophagus. J Clin Pathol 2005; 58: 904-910.
102. Evangelou K, Kotsinas A, Mariolis-Sapsakos T, Giannopoulos A, Tsantoulis PK, Constantinides C et al. E2F-1 overexpression correlates with decreased proliferation and better prognosis in adenocarcinomas of Barrett oesophagus. J Clin Pathol 2008; 61: 601-605.
103. Yasui W, Yokozaki H, Fujimoto J, Naka K, Kuniyasu H, Tahara E. Genetic and epigenetic alterations in multistep carcinogenesis of the stomach. J Gastroenterol 2000; 35(Suppl 12): 111-115.
104. Yasui W, Naka K, Suzuki T, Fujimoto J, Hayashi K, Matsutani N et al. Expression of p27Kip1, cyclin E and E2F-1 in primary and metastatic tumors of gastric carcinoma. Oncology Rep 1999; 6: 983-987.
105. Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T, Tahara E. Expression of the E2F family in human gastrointestinal carcinomas. Int J Cancer 1999; 81: 535-538.
106. Wu JG, Yu JW, Wu HB, Zheng LH, Ni XC, Li XQ et al. Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma. BMC Res Notes 2014; 7: 6.
107. Atienza Jr. C, Elliott MJ, Dong YB, Yang HL, Stilwell A, Liu TJ et al. Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors. Int J Mol Med 2000; 6: 55-63.
108. Xiao Q, Li L, Xie Y, Tan N, Wang C, Xu J et al. Transcription factor E2F-1 is upregulated in human gastric cancer tissues and its overexpression suppresses gastric tumor cell proliferation. Cell Oncol 2007; 29: 335-349.
109. Xie Y, Wang C, Li L, Ma Y, Yin Y, Xiao Q. Overexpression of E2F-1 inhibits progression of gastric cancer in vitro. Cell BiolInt 2009; 33: 640-649.
110. Haller F, Gunawan B, von Heydebreck A, Schwager S, Schulten HJ, Wolf-Salgo J et al. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors. Clinical Cancer Res 2005; 11: 6589-6597.
111. Mitomi H, Fukui N, Kishimoto I, Tanabe S, Kikuchi S, Saito T et al. Role for p16(INK4a) in progression of gastrointestinal stromal tumors of the stomach: alteration of p16(INK4a) network members. Hum Pathol 2011; 42: 1505-1513.
112. Alonso MM, Fueyo J, Shay JW, Aldape KD, Jiang H, Lee OH et al. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J Natl Cancer Inst 2005; 97: 1589-1600.
113. Gomez-Manzano C, Lemoine MG, Hu M, He J, Mitlianga P, Liu TJ et al. Adenovirallymediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int J Oncol 2001; 19: 359-365.
114. Palaiologou M, Koskinas J, Karanikolas M, Fatourou E, Tiniakos DG. E2F-1 is overexpressed and pro-apoptotic in human hepatocellular carcinoma. Virchows Arch 2012; 460: 439-446.
115. Midorikawa Y, Makuuchi M, Tang W, Aburatani H. Microarray-based analysis for hepatocellular carcinoma: from gene expression profiling to new challenges. World J Gastroenterol 2007; 13: 1487-1492.
116. Midorikawa Y, Tsutsumi S, Nishimura K, Kamimura N, Kano M, Sakamoto H et al. Distinct chromosomal bias of gene expression signatures in the progression of hepatocellular carcinoma. Cancer Res 2004; 64: 7263-7270.
117. Chen YL, Uen YH, Li CF, Horng KC, Chen LR, Wu WR et al. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma. Ann Surg Oncol 2013; 20: 4041-4054.
118. Simile MM, De Miglio MR, Muroni MR, Frau M, Asara G, Serra S et al. Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells. Carcinogenesis 2004; 25: 333-341.
119. Wang C, Xiao Y, Hu Z, Chen Y, Liu N, Hu G. PEG10 directly regulated by E2Fs might have a role in the development of hepatocellular carcinoma. FEBS Lett 2008; 582: 2793-2798.
120. Pascale RM, Simile MM, De Miglio MR, Muroni MR, Calvisi DF, Asara G et al. Cell cycle deregulation in liver lesions of rats with and without genetic predisposition to hepatocarcinogenesis. Hepatology 2002; 35: 1341-1350.
121. Conner EA, Lemmer ER, Omori M, Wirth PJ, Factor VM, Thorgeirsson SS. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene 2000; 19: 5054-5062.
122. Imai MA, Oda Y, Oda M, Nakanishi I, Kawahara E. Overexpression of E2F1 associated with LOH at RB locus and hyperphosphorylation of RB in non-small cell lung carcinoma. J Cancer Res Clin Oncol 2004; 130: 320-326.
123. Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K et al. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clinical Cancer Res 2007; 13: 6938-6946.
124. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y et al. High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci USA 2005; 102: 9625-9630.
125. Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D et al. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 2002; 198: 142-156.
126. Nicholson SA, Okby NT, Khan MA, Welsh JA, McMenamin MG, Travis WD et al. Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Res 2001; 61: 5636-5643.
127. Eymin B, Gazzeri S, Brambilla C, Brambilla E. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene 2001; 20: 1678-1687.
128. Coe BP, Thu KL, Aviel-Ronen S, Vucic EA, Gazdar AF, Lam S et al. Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer. PLoS One 2013; 8: e71670.
129. Hubaux R, Thu KL, Coe BP, MacAulay C, Lam S, Lam WL. EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation. J Thora Oncol 2013; 8: 1102-1106.
130. Peters HL, Yan Y, Nordgren TM, Cutucache CE, Joshi SS, Solheim JC. Amyloid precursor-like protein 2 suppresses irradiation-induced apoptosis in Ewing sarcoma cells and is elevated in immune-evasive Ewing sarcoma cells. Cancer Biol Ther 2013; 14: 752-760.
131. Dong YB, Yang HL, Elliott MJ, Liu TJ, Stilwell A, Atienza C Jr et al. Adenovirus-mediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells. Cancer 1999; 86: 2021-2033.
132. Furukawa Y, Nishimura N, Satoh M, Endo H, Iwase S, Yamada H et al. Apaf-1 is a mediator of E2F-1-induced apoptosis. J Biol Chem 2002; 277: 39760-39768.
133. Hao H, Dong Y, Bowling MT, Gomez-Gutierrez JG, Zhou HS, McMasters KM. E2F-1 induces melanoma cell apoptosis via PUMA up-regulation and Bax translocation. BMC Cancer 2007; 7: 24.
134. Du Y, Zhang S, Wang Z, Zhou W, Luan M, Yang X et al. Induction of apoptosis and cell cycle arrest by NS398 in oral squamous cell carcinoma cells via downregulation of E2 promoter-binding factor-1. Oncology Rep 2008; 20: 605-611.
135. Kwong RA, Nguyen TV, Bova RJ, Kench JG, Cole IE, Musgrove EA et al. Overexpression of E2F-1 is associated with increased disease-free survival in squamous cell carcinoma of the anterior tongue. Clinical Cancer Res 2003; 9(10 Pt 1): 3705-3711.
136. De Meyer T, Bijsmans IT, Van de Vijver KK, Bekaert S, Oosting J, Van Criekinge W et al. E2Fs mediate a fundamental cell-cycle deregulation in high-grade serous ovarian carcinomas. J Pathol 2009; 217: 14-20.
137. Suh DS, Yoon MS, Choi KU, Kim JY. Significance of E2F-1 overexpression in epithelial ovarian cancer. Int J Gynecol Cancer 2008; 18: 492-498.
138. Reimer D, Sadr S, Wiedemair A, Goebel G, Concin N, Hofstetter G et al. Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann N Y Acad Sci 2006; 1091: 270-281.
139. Hallstrom TC, Mori S, Nevins JR. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 2008; 13: 11-22.
140. Yamazaki K, Yajima T, Nagao T, Shinkawa H, Kondo F, Hanami K et al. Expression of transcription factor E2F-1 in pancreatic ductal carcinoma: an immunohistochemical study. Pathol Res Pract 2003; 199: 23-28.